Cytokinetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

CEO
Robert I. Blum
CEORobert I. Blum
Employees
498
Employees498
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1997
Founded1997
Employees
498
Employees498

CYTK Key Statistics

Market cap
7.62B
Market cap7.62B
Price-Earnings ratio
-9.55
Price-Earnings ratio-9.55
Dividend yield
Dividend yield
Average volume
1.59M
Average volume1.59M
High today
$62.71
High today$62.71
Low today
$61.00
Low today$61.00
Open price
$61.31
Open price$61.31
Volume
1.74M
Volume1.74M
52 Week high
$70.98
52 Week high$70.98
52 Week low
$29.31
52 Week low$29.31

Stock Snapshot

The current Cytokinetics(CYTK) stock price is $62.50, with a market capitalization of 7.62B. The stock trades at a price-to-earnings (P/E) ratio of -9.55.

On 2026-02-06, Cytokinetics(CYTK) stock traded between a low of $61.00 and a high of $62.71. Shares are currently priced at $62.50, which is +2.5% above the low and -0.3% below the high.

Cytokinetics(CYTK) shares are trading with a volume of 1.74M, against a daily average of 1.59M.

In the last year, Cytokinetics(CYTK) shares hit a 52-week high of $70.98 and a 52-week low of $29.31.

In the last year, Cytokinetics(CYTK) shares hit a 52-week high of $70.98 and a 52-week low of $29.31.

CYTK News

Simply Wall St 2d
MYQORZO Approval Shifts Cytokinetics Toward Commercial Growth And Valuation Upside

FDA approves MYQORZO (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in the U.S. U.S. commercial launch of MYQORZO begins, making th...

MYQORZO Approval Shifts Cytokinetics Toward Commercial Growth And Valuation Upside
TipRanks 3d
Cytokinetics price target raised to $92 from $84 at Truist

Truist analyst Srikripa Devarakonda raised the firm’s price target on Cytokinetics (CYTK) to $92 from $84 and keeps a Buy rating on the shares. Ahead of Q4 resu...

TipRanks 4d
Top Cytokinetics Executive Just Cashed Out in a Notable Insider Move

New insider activity at Cytokinetics ( (CYTK) ) has taken place on February 2, 2026. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful in...

Analyst ratings

81%

of 21 ratings
Buy
81%
Hold
19%
Sell
0%

More CYTK News

Simply Wall St 7d
The Bull Case For Cytokinetics Could Change Following MYQORZO’s FDA-Backed Commercial Debut – Learn Why

Cytokinetics has launched MYQORZO (aficamten) in the U.S. following FDA approval for adults with symptomatic obstructive hypertrophic cardiomyopathy, supported...

The Bull Case For Cytokinetics Could Change Following MYQORZO’s FDA-Backed Commercial Debut – Learn Why

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.